Reduction of Product-related Impurities during Production of recombinant Adeno-Associated Viruses
ByDr. Michelle Hussong, Head of Molecular Biology - Technology and Assay Development, CEVEC Pharmaceuticals GmbH,Dr. Tobias Bonifert, Head of Vector Technology, CEVEC Pharmaceuticals GmbH,Prof. Dr. Nico Scheer, Senior Consultant Business Development, CEVEC Pharmaceuticals GmbH, Professor in Molecular Biology at FH Aachen, University of Applied Sciences, Germany
Biopharma Insights-Thought Leadership from Marketers | Paid Program